Core Viewpoint - Kubo Medical (02216) has seen a significant increase in stock price, rising over 9% during trading and currently up 5.86% at HKD 3.25, with a trading volume of HKD 11.79 million [1] Group 1: Company Actions - Kubo Medical announced plans to issue a total of 105 million subscription shares at a price of HKD 3.11 per share, representing a premium of approximately 1.3% over the previous trading day's closing price [1] - The net proceeds from this issuance are expected to be around HKD 327 million, which will be used for potential acquisitions in the medical device industry to continue expanding the product portfolio [1] - The company is actively seeking potential acquisition targets within the medical device sector and is currently in discussions with various parties [1] Group 2: Strategic Partnerships - Notably, Ying Tai Medical (01501) plans to invest approximately HKD 283 million to subscribe for about 91.09 million shares of Kubo Medical [1] - The announcement highlights that Kubo Medical has a rich product line in the non-vascular interventional field, and the subscription will further enhance the company's strategic positioning in this area [1]

Core Viewpoint - Kintor Pharmaceutical-B (02216) has seen a significant increase in stock price, rising over 9% during trading, with a current price of 3.25 HKD and a trading volume of 11.79 million HKD. The company announced plans to issue a total of 105 million subscription shares at a price of 3.11 HKD per share, representing a premium of approximately 1.3% over the previous closing price. The net proceeds of approximately 327 million HKD will be used for potential acquisitions in the medical device industry, as the company seeks to expand its product portfolio [1][1][1]. Group 1 - Kintor Pharmaceutical plans to issue 105 million subscription shares at 3.11 HKD each, raising approximately 327 million HKD for acquisitions [1][1][1]. - The stock price of Kintor Pharmaceutical has increased by over 9% during trading, reflecting positive market sentiment [1][1][1]. - The company is currently in discussions with various parties to identify potential acquisition targets in the medical device sector [1][1][1]. Group 2 - Ying Tai Medical (01501) intends to invest approximately 283 million HKD to subscribe for about 91.09 million shares of Kintor Pharmaceutical [1][1][1]. - The subscription is expected to enhance Kintor Pharmaceutical's strategic positioning in the non-vascular interventional field, where it already has a rich product line [1][1][1].

格隆汇10月10日丨瑛泰医疗(01501.HK)公告，于2025年10月10日，公司与堃博医疗订立认购协议，据 此，公司有条件同意认购，而堃博医疗有条件同意向公司发行合共9109万股认购股份，认购价为每股认 购股份3.11港元，较联交所所报收市价溢价约1.30%；总代价为2.83亿港元(不包括交易成本)，惟须受认 购协议所载条款及条件规限。 鉴于上文所述，董事(包括独立非执行董事)认为认购协议的条款属公平合理、按一般商业条款订立，且 符合公司及股东的整体利益。 于完成后，公司将合共持有9109万股堃博医疗股份，分别相当于堃博医疗于本公告日期已发行堃博医疗 股份约17.24%(若不计算库存股，则为约17.30%)及因本次发行认购股份而扩大之堃博医疗已发行堃博医 疗股份约14.38%(若不计算库存股，则为约14.42%)，堃博医疗的财务业绩将不会综合计入集团的账目。 堃博医疗是全球介入呼吸病学领域的创新企业，聚焦肺部疾病微创介入诊疗产品的研发，尤其是慢阻肺 及肺癌的介入治疗，其Inter Vaporr®热蒸汽治疗系统(慢阻肺治疗)、Bronc Ablater®智衡?射频消融系统 (肺癌治疗)、TLD靶向去神经消融 ...

公告称，考虑到堃博医疗在非血管介入领域的产品线丰富，认购事项可进一步拓展公司在非血管介入领 域的战略布局。 瑛泰医疗(01501)公布，于2025年10月10日(交易时段后)，该公司与堃博医疗订立认购协议，据此，堃博 医疗有条件同意向该公司发行合共91,093,613股认购股份，认购价为每股认购股份3.11港元，总代价为 283,301,136.43港元(不包括交易成本)，惟须受认购协议所载条款及条件规限。 于完成后，该公司将合共持有91,093,613股堃博医疗股份，分别相当于堃博医疗于本公告日期已发行堃 博医疗股份约17.24%(若不计算库存股，则为约17.30%)及因本次发行认购股份而扩大的堃博医疗已发行 堃博医疗股份约14.38%(若不计算库存股，则为约14.42%)，堃博医疗的财务业绩将不会综合计入集团的 账目。 ...

智通财经APP讯，瑛泰医疗(01501)公布，于2025年10月10日(交易时段后)，该公司与堃博医疗订立认购 协议，据此，堃博医疗有条件同意向该公司发行合共91,093,613股认购股份，认购价为每股认购股份 3.11港元，总代价为283,301,136.43港元(不包括交易成本)，惟须受认购协议所载条款及条件规限。 公告称，考虑到堃博医疗在非血管介入领域的产品线丰富，认购事项可进一步拓展公司在非血管介入领 域的战略布局。 于完成后，该公司将合共持有91,093,613股堃博医疗股份，分别相当于堃博医疗于本公告日期已发行堃 博医疗股份约17.24%(若不计算库存股，则为约17.30%)及因本次发行认购股份而扩大的堃博医疗已发行 堃博医疗股份约14.38%(若不计算库存股，则为约14.42%)，堃博医疗的财务业绩将不会综合计入集团的 账目。 ...

（ 於中華人民共和國註冊成立的股份有限公司 ） （股份代號：1501） 須予披露交易 認購堃博醫療控股有限公司新股份 香 港 交易 及 結 算 所 有限 公 司 及 香港 聯 合 交 易 所有 限 公 司 對 本公 告 的 內 容概 不 負 責， 對 其 準 確 性或 完 整 性 亦不 發 表 任 何 聲明 ， 並 明 確 表示 ， 概 不 對因 本 公 告全 部 或 任 何 部分 內 容 而 產生 或 因 倚 賴 該等 內 容 而 引 致的 任 何 損 失承 擔任何責任。 本公告僅供參考，並不構成收購、購買或認購任何證券之邀請或要約。 Shanghai INT Medical Instruments Co., Ltd. * 上 海 瑛 泰 醫 療 器 械 股 份 有 限 公 司 上市規則的涵義 於完成後，本公司將合共持有91,093,613股堃博醫療股份，分別相當於堃博 醫療於本公告日期已發行堃博醫療股份約17.24%（ 若不計算庫存股，則為約 17.30% ）及 因 本 次 發 行 認 購 股 份 而 擴 大 之 堃 博 醫 療 已 發 行 堃 博 醫 療 股 份 約 14.38%（ 若不計算庫存股，則為 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 上海瑛泰醫療器械股份有限公司 (於中華人民共和國註冊成立的股份有限公司） 呈交日期: 2025年10月8日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01501 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 104,213,392 | RMB | | 1 RMB | | 104,213,392 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 104,213,392 | RMB | | 1 RMB | | 104,213,392 | | 2. 股份 ...

[Company Information](index=3&type=section&id=Company%20Information) This section provides essential corporate details, including the composition of the Board of Directors, Supervisors, and senior management, as well as information on auditors, legal advisors, and key operational locations [Directors, Supervisors, and Senior Management](index=3&type=section&id=Directors%2C%20Supervisors%2C%20and%20Senior%20Management) The company's Board of Directors comprises executive, non-executive, and independent non-executive directors, with a separate Supervisory Committee and defined audit, remuneration, and nomination committees - Executive Directors include **Dr. Liang Dongke** (Chairman) and **Mr. Lin Sen**[7](index=7&type=chunk) - Non-executive Directors include **Dr. Song Yuan**, **Mr. Wang Ruiqin**, **Ms. Chen Hongqin**, and **Mr. Zhang Hong**, who was appointed on **May 23, 2025**[7](index=7&type=chunk) - Independent Non-executive Directors are **Mr. Jian Xigao**, **Mr. Xu Hongqun**, and **Mr. Xu Congli**[7](index=7&type=chunk) - The Supervisory Committee Chairman is **Ms. Ma Huifang**, with members **Ms. Chen Jie** and **Mr. Shen Xiaoru**[7](index=7&type=chunk) [Auditors and Legal Advisors](index=3&type=section&id=Auditors%20and%20Legal%20Advisors) The company's international auditor is KPMG, with KPMG Huazhen LLP (Special General Partnership) serving as the domestic auditor, while legal counsel is provided by O'Melveny & Myers LLP for Hong Kong law and DeHeng Law Offices (Shanghai) for PRC law - The international auditor is **KPMG**[7](index=7&type=chunk) - The domestic auditor is **KPMG Huazhen LLP (Special General Partnership)**[7](index=7&type=chunk) - Hong Kong legal counsel is **O'Melveny & Myers LLP**, and PRC legal counsel is **DeHeng Law Offices (Shanghai)**[7](index=7&type=chunk) [Registered Office and Principal Place of Business](index=3&type=section&id=Registered%20Office%20and%20Principal%20Place%20of%20Business) The company's PRC registered office and headquarters are located at Building 2, No. 925 Jinyuan 1st Road, Jiading District, Shanghai, with its principal place of business in Hong Kong at 31/F, Two Times Square, 1 Matheson Street, Causeway Bay - PRC Registered Office and Headquarters: Building 2, No. 925 Jinyuan 1st Road, Jiading District, Shanghai, China[8](index=8&type=chunk)[9](index=9&type=chunk) - Hong Kong Principal Place of Business: 31/F, Two Times Square, 1 Matheson Street, Causeway Bay, Hong Kong[9](index=9&type=chunk) [H Share Registrar and Principal Banks](index=4&type=section&id=H%20Share%20Registrar%20and%20Principal%20Banks) The company's H Share Registrar is Hong Kong Registrars Limited, with principal banks including China Construction Bank Corporation Shanghai Jiangqiao Branch and Agricultural Bank of China Limited Shanghai Jiading Branch, and its stock code is 1501 - H Share Registrar: **Hong Kong Registrars Limited**[9](index=9&type=chunk) - Principal Banks: **China Construction Bank Corporation Shanghai Jiangqiao Branch**, **Agricultural Bank of China Limited Shanghai Jiading Branch**[9](index=9&type=chunk) - Stock Code: **1501**[9](index=9&type=chunk) [Interim Results Highlights](index=5&type=section&id=Interim%20Results%20Highlights) This section summarizes the group's financial performance for the six months ended June 30, 2025, detailing revenue growth, changes in gross margin and profit, and earnings per share [Financial Highlights](index=5&type=section&id=Financial%20Highlights) For the six months ended June 30, 2025, the Group's revenue increased by 17.52% to RMB 461.08 million, driven by higher sales of interventional medical devices and agency business, while gross margin decreased to 58.70% and profit for the period grew by 3.29% to RMB 102.44 million, with no interim dividend declared Financial Highlights for the Six Months Ended June 30 | Indicator | 2025 (RMB thousands) | 2024 (RMB thousands) | Change | | :--- | :--- | :--- | :--- | | Revenue | 461,075 | 392,322 | 17.52% | | Gross Profit | 270,661 | 246,768 | 9.68% | | Profit for the Period | 102,436 | 99,178 | 3.29% | | Basic Earnings Per Share (RMB) | 0.57 | 0.58 | -1.72% | | Diluted Earnings Per Share (RMB) | 0.57 | 0.58 | -1.72% | - Revenue growth was primarily due to increased sales of interventional medical devices (**+13.57%** to **RMB 392.37 million**) and a significant increase in agency business sales (**+118.69%** to **RMB 32.41 million**)[11](index=11&type=chunk) - Gross margin decreased from **62.90%** to **58.70%**, mainly due to increased sales of lower-margin agency business[11](index=11&type=chunk) - The Board has resolved not to declare any interim dividend for the reporting period[11](index=11&type=chunk) [Management Discussion and Analysis](index=6&type=section&id=Management%20Discussion%20and%20Analysis) This section provides an in-depth review of the Group's business operations, strategic initiatives, financial performance, and future outlook, covering key developments and financial metrics [Business Overview](index=6&type=section&id=Business%20Overview) Shanghai Yingtai Medical Device Co., Ltd. is a leading Chinese manufacturer of interventional cardiology devices with a complete industry chain, benefiting from government healthcare reforms and leveraging its extensive product registrations, strong R&D capabilities, and broad distribution network for competitive advantage - The Group is a leading Chinese manufacturer of interventional cardiology devices, possessing a complete industry chain, with main products used in vascular interventional surgeries[12](index=12&type=chunk) - Chinese government policies, such as DRG/DIP payment reform and volume-based procurement for medical consumables, provide the company with a competitive advantage[13](index=13&type=chunk) - As of **June 30, 2025**, the company holds **43** NMPA Class III medical device registration certificates, **68** provincial/municipal Class II medical device registration certificates, **27** CE certifications, and **25** FDA approvals[15](index=15&type=chunk) - As of **June 30, 2025**, the company owns **657** registered patents, **281** pending patent applications, and **28** registered software copyrights[17](index=17&type=chunk) - The distribution network covers **3,735** hospitals across **23** provinces, **4** municipalities, and **5** autonomous regions in China, as well as **313** overseas customers in **91** countries and regions[18](index=18&type=chunk) [Review of Activities](index=7&type=section&id=Review%20of%20Activities) During the reporting period, the Group actively expanded its business footprint and investment portfolio by increasing the number of subsidiaries, establishing joint ventures and limited partnerships, and acquiring a controlling interest in Hangzhou Weiqiang Medical Technology Co., Ltd., while also optimizing corporate governance through the re-election and appointment of directors and supervisors [Subsidiaries](index=7&type=section&id=Subsidiaries) As of June 30, 2025, the Group's number of wholly-owned or controlled subsidiaries increased to 24 from 19 at the end of 2024, focusing on the design and development of interventional/implantable medical devices across various fields and medical device production equipment - As of **June 30, 2025**, the Group owns **24** wholly-owned or controlled subsidiaries, an increase from **19** as of **December 31, 2024**[19](index=19&type=chunk) - The business scope of subsidiaries covers the design and development of interventional/implantable medical devices in cardiovascular, neurological, peripheral, ENT, and urological fields, as well as medical device production equipment and molds[19](index=19&type=chunk) [Establishment of Joint Ventures](index=7&type=section&id=Establishment%20of%20Joint%20Ventures) On November 28, 2024, the company entered into investment agreements with related parties Mr. Lin Sen, Dr. Song Yuan, and Mr. Wang Ruiqin to establish Shanghai Yingtai Investment Management Co., Ltd. (for investment management) and Shanghai Yingtai Shenghuo Trading Co., Ltd. (for sales of cosmetics, health products, and disposable medical products), with these transactions constituting connected transactions but exempted from certain Listing Rules requirements - Established Shanghai Yingtai Investment Management Co., Ltd., primarily engaged in investment management[20](index=20&type=chunk) - Established Shanghai Yingtai Shenghuo Trading Co., Ltd., primarily engaged in sales of cosmetics, health products, and disposable medical products[20](index=20&type=chunk) - Related transactions involved connected persons, constituting connected transactions, but were exempted from certain Listing Rules requirements due to applicable percentage ratios being below **5.0%**[20](index=20&type=chunk) [Establishment of Limited Partnerships](index=8&type=section&id=Establishment%20of%20Limited%20Partnerships) On February 27, 2025, the company entered into a partnership agreement with several partners to establish Shanghai Chenyao Xinchen Private Investment Fund Partnership (Limited Partnership) ("Chenyao Xinchen Fund"), committing RMB 100.0 million, which constitutes a discloseable transaction but is exempted from shareholder approval requirements - The company, as a limited partner, invested **RMB 100.0 million** to establish Shanghai Chenyao Xinchen Private Investment Fund Partnership (Limited Partnership)[21](index=21&type=chunk) - This investment constitutes a discloseable transaction but is exempted from shareholder approval requirements as the applicable percentage ratios are below **25%**[21](index=21&type=chunk) [Re-election and Appointment of Directors and Supervisors](index=8&type=

Shanghai INT Medical Instruments Co., Ltd. * 上 海 瑛 泰 醫 療 器 械 股 份 有 限 公 司 （ 於中華人民共和國註冊成立的股份有限公司 ） 香 港 交易 及 結 算 所 有限 公 司 及 香港 聯 合 交 易 所有 限 公 司 對 本公 告 之 內 容概 不 負 責， 對 其 準 確 性或 完 整 性 亦不 發 表 任 何 聲明 ， 並 明 確 表示 ， 概 不 就因 本 公 告全 部 或 任 何 部分 內 容 而 產生 或 因 倚 賴 該等 內 容 而 引 致之 任 何 損 失承 擔任何責任。 1. 目標公司的背景及財務資料 （股份代號：1501） 補充公告 須予披露交易 建議收購目標公司控股權益 茲提述上海瑛泰醫療器械股份有限公司（「本公司」）日期為2024年12月18日 及2025年5月21日之公告（「該等公告」），內容有關收購目標公司控股權益之 須 予 披露 交 易 。 除 文義 另 有 所 指外 ， 本 公 告 所用 詞 彙 與 該 等公 告 所 界 定者 具有相同涵義。 目標公司於2016年5月成立，專注於外周血管介入醫療器械的研發、生 產、銷 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 上海瑛泰醫療器械股份有限公司 (於中華人民共和國註冊成立的股份有限公司） 呈交日期: 2025年9月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01501 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 104,213,392 | RMB | | 1 RMB | | 104,213,392 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 104,213,392 | RMB | | 1 RMB | | 104,213,392 | 本月底法定/註冊 ...